X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 34.6 -9.9 - View Chart
P/BV x 10.0 0.2 6,523.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
VENUS REMEDIES
Mar-17
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs5,190143 3,634.5%   
Low Rs4,35165 6,693.8%   
Sales per share (Unadj.) Rs1,382.9324.2 426.6%  
Earnings per share (Unadj.) Rs130.26.4 2,031.0%  
Cash flow per share (Unadj.) Rs137.940.6 339.9%  
Dividends per share (Unadj.) Rs40.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs652.7366.0 178.3%  
Shares outstanding (eoy) m21.2512.34 172.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,076.3%   
Avg P/E ratio x36.616.2 226.1%  
P/CF ratio (eoy) x34.62.6 1,350.8%  
Price / Book Value ratio x7.30.3 2,574.5%  
Dividend payout %30.70-   
Avg Mkt Cap Rs m101,3731,282 7,906.6%   
No. of employees `0003.10.9 341.4%   
Total wages/salary Rs m3,453251 1,375.6%   
Avg. sales/employee Rs Th9,531.94,430.1 215.2%   
Avg. wages/employee Rs Th1,119.9278.0 402.9%   
Avg. net profit/employee Rs Th897.387.6 1,024.4%   
INCOME DATA
Net Sales Rs m29,3874,000 734.6%  
Other income Rs m57623 2,539.2%   
Total revenues Rs m29,9634,023 744.8%   
Gross profit Rs m3,973785 506.3%  
Depreciation Rs m164422 39.0%   
Interest Rs m20344 5.9%   
Profit before tax Rs m4,36542 10,367.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,598-37 -4,320.0%   
Profit after tax Rs m2,76779 3,497.5%  
Gross profit margin %13.519.6 68.9%  
Effective tax rate %36.6-87.9 -41.7%   
Net profit margin %9.42.0 476.1%  
BALANCE SHEET DATA
Current assets Rs m18,9062,606 725.4%   
Current liabilities Rs m6,2971,980 318.0%   
Net working cap to sales %42.915.6 274.2%  
Current ratio x3.01.3 228.1%  
Inventory Days Days62128 48.5%  
Debtors Days Days2243 50.2%  
Net fixed assets Rs m1,1595,353 21.6%   
Share capital Rs m213123 172.2%   
"Free" reserves Rs m13,6574,393 310.9%   
Net worth Rs m13,8694,516 307.1%   
Long term debt Rs m01,618 0.0%   
Total assets Rs m20,6388,291 248.9%  
Interest coverage x215.01.1 19,150.8%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.40.5 295.1%   
Return on assets %13.55.1 264.8%  
Return on equity %19.91.8 1,138.8%  
Return on capital %31.66.3 502.7%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m00-   
Fx outflow Rs m0736 0.0%   
Net fx Rs m0-736 0.0%   
CASH FLOW
From Operations Rs m3,072997 308.1%  
From Investments Rs m-1,554-461 336.9%  
From Financial Activity Rs m-898-571 157.2%  
Net Cashflow Rs m621-35 -1,767.8%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FULFORD INDIA  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT LTD.  SUVEN LIFE  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 15, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS